Impact of Multimorbidity Burden on Mortality Risk among Colon Cancer Survivors.

IF 3.3 3区 医学 Q2 ONCOLOGY Journal of Cancer Pub Date : 2025-01-01 DOI:10.7150/jca.103438
Su-Hung Wang, Mitsuhiro Koseki, Ming-Jen Sheu, Huang-Lan Li, Ying-Jia Lin, Ching-Chieh Yang, Chung-Han Ho
{"title":"Impact of Multimorbidity Burden on Mortality Risk among Colon Cancer Survivors.","authors":"Su-Hung Wang, Mitsuhiro Koseki, Ming-Jen Sheu, Huang-Lan Li, Ying-Jia Lin, Ching-Chieh Yang, Chung-Han Ho","doi":"10.7150/jca.103438","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> Multimorbidity among colon cancer survivors reflected the coexistence of multiple chronic conditions. This study aimed to understand the comorbidity risks for long-term colon cancer survivors using a real-world population database. <b>Methods:</b> Taiwan cancer registry from 2016 to 2021 identified patients diagnosed with colon cancer, selecting those who survived beyond five years. Charlson Comorbidity Index (CCI) was used to assess the level of comorbidities, categorizing patients into no (CCI=0), mild (CCI=1-2), and severe (CCI≥3) comorbidity groups, for estimating the impact on survival. Cox regression model was applied to estimate risk factors associated with comorbidities among long-term colon cancer survivors. <b>Results:</b> In this cohort study of 13,209 colon cancer survivors, most had no comorbidity (82.23%), following as mild (10.03%) and severe (7.74%) comorbidity. Our study revealed the significant association between higher CCI scores and increased mortality risk. Compared with patients without comorbidities, mild comorbidities patients exhibited a significantly higher risk of mortality (HR:4.56; 95% CI:3.93-5.28), and those with severe comorbidities had an increased risk (HR:12.67; 95% CI:11.15-14.40) after adjusting potential confounders. Subgroup of sex, age, clinical stage, and treatment types show that colon cancer survivors with mild/severe comorbidities had significant higher mortality risk than those without comorbidities. <b>Conclusion:</b> This study indicated the critical role of comorbidity management may improve the survival outcomes for colon cancer patients, particularly those with high-risk factors and severe comorbidities.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"16 2","pages":"558-566"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685689/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.103438","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Multimorbidity among colon cancer survivors reflected the coexistence of multiple chronic conditions. This study aimed to understand the comorbidity risks for long-term colon cancer survivors using a real-world population database. Methods: Taiwan cancer registry from 2016 to 2021 identified patients diagnosed with colon cancer, selecting those who survived beyond five years. Charlson Comorbidity Index (CCI) was used to assess the level of comorbidities, categorizing patients into no (CCI=0), mild (CCI=1-2), and severe (CCI≥3) comorbidity groups, for estimating the impact on survival. Cox regression model was applied to estimate risk factors associated with comorbidities among long-term colon cancer survivors. Results: In this cohort study of 13,209 colon cancer survivors, most had no comorbidity (82.23%), following as mild (10.03%) and severe (7.74%) comorbidity. Our study revealed the significant association between higher CCI scores and increased mortality risk. Compared with patients without comorbidities, mild comorbidities patients exhibited a significantly higher risk of mortality (HR:4.56; 95% CI:3.93-5.28), and those with severe comorbidities had an increased risk (HR:12.67; 95% CI:11.15-14.40) after adjusting potential confounders. Subgroup of sex, age, clinical stage, and treatment types show that colon cancer survivors with mild/severe comorbidities had significant higher mortality risk than those without comorbidities. Conclusion: This study indicated the critical role of comorbidity management may improve the survival outcomes for colon cancer patients, particularly those with high-risk factors and severe comorbidities.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多病负担对结肠癌幸存者死亡风险的影响
目的:结肠癌幸存者的多发病反映了多种慢性疾病的共存。本研究旨在利用真实世界人口数据库了解长期结肠癌幸存者的合并症风险。方法:台湾癌症登记处2016年至2021年诊断为结肠癌的患者,选择存活5年以上的患者。Charlson共病指数(CCI)用于评估合并症的水平,将患者分为无(CCI=0)、轻度(CCI=1-2)和重度(CCI≥3)合并症组,以评估对生存的影响。采用Cox回归模型对长期结肠癌幸存者中与合并症相关的危险因素进行评估。结果:在13209例结肠癌幸存者的队列研究中,大多数没有合并症(82.23%),其次是轻度(10.03%)和重度(7.74%)合并症。我们的研究揭示了较高的CCI评分与死亡风险增加之间的显著关联。与无合并症的患者相比,轻度合并症患者的死亡风险显著高于无合并症患者(HR:4.56;95% CI:3.93-5.28),严重合并症患者的风险增加(HR:12.67;95% CI:11.15-14.40)。性别、年龄、临床分期和治疗类型的亚组显示,有轻度/重度合并症的结肠癌幸存者的死亡风险明显高于无合并症的结肠癌幸存者。结论:本研究表明,合并症管理可以改善结肠癌患者的生存结果,特别是那些有高危因素和严重合并症的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Cancer
Journal of Cancer ONCOLOGY-
CiteScore
8.10
自引率
2.60%
发文量
333
审稿时长
12 weeks
期刊介绍: Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.
期刊最新文献
ADAM10 is a key player in the diagnosis, prognosis and metastasis of non-small cell lung cancer (NSCLC). Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer. KLK7 Involvement in Thyroid Papillary Carcinoma Cell Migration and Invasion by EMT via MAPK/ERK Pathways. NUPR1 contributes to endocrine therapy resistance by modulating BIRC5 expression and inducing luminal B-ERBB2+ subtype-like characteristics in estrogen receptor-positive breast cancer cells. The Impact of MET Variants in Oral Cancer Progression and Clinicopathological Characteristics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1